Tag:
Johnson & Johnson
Latest Headlines
Latest Headlines
J&J pressured to settle Australian hip lawsuits
Johnson & Johnson's $8.3 million defeat in a U.S. jury trial over its ASR metal-on-metal hip implant could force it to settle a massive class action lawsuit in Australia over the same product.
J&J recalls LifeScan glucose meters over shutdown risk
Johnson & Johnson is recalling a model of its market-leading LifeScan glucose meters, warning that the devices shut down when confronted with dangerously high blood sugar levels.
J&J fights $327M Risperdal verdict, saying no one was harmed
South Carolina Circuit Judge Roger Couch took a particularly creative approach when he levied a $327 million penalty against Johnson & Johnson in the state's Risperdal case.
J&J metal hip problems keep erupting in the trenches
As if 8,000-plus lawsuits alleging faulty all metal helps weren't enough, Johnson & Johnson/DePuy data from an Illinois hospital suggests that repeat surgeries for patients dealing with the implants keep rising.
Bayer using DKSH for distribution in Cambodia
The logistics of getting drugs delivered in underdeveloped countries can be tricky. Many companies turn to partners with the expertise that can help them navigate the import laws and distribution obstacles that those countries present.
Biopharma's Top R&D Spenders - 2012
Add up the top-line R&D spending for the top 10 pharma companies in the world and you'd think that nothing had changed from 2011 to 2012. But you'd be very wrong. Big Pharma's heavy hitters in R&D have a wildly mixed record in a fast-changing field. It will be an interesting year ahead. Here's a look at last year's results, and an analysis of where they point. Read the report >>
J&J's internal docs say recalled hip was defective
A Johnson & Johnson executive testified that the company recalled its all-metal hip replacements because they didn't meet "clinical expectations," not because they were defective, but that doesn't quite jibe with internal documents.
Ex-J&J chief's 2012 pay outclasses Gorsky's by almost 3-to-1
The question isn't why Johnson & Johnson CEO Alex Gorsky took a 10% hit to his incentive pay. It's why Chairman William Weldon didn't suffer a bigger cut in his pay.
J&J opens new innovation center in quest for more early-stage deals
Johnson & Johnson has prominently planted its R&D flag in London. Today the giant pharma company officially opened up its new innovation center in the U.K., one of four scientific and business development outposts around the world charged with building J&J's ties to the biotech industry and academia as it fosters new development deals.
J&J's Cordis grabs Flexible Stenting Solutions in diversification move
Johnson & Johnson's Cordis has snatched up a New Jersey maker of self-expanding, flexible stents, with the idea of expanding its own offerings in the technology to treat peripheral artery disease.
